Assembly Biosciences (ASMB) AI Stock Analysis

• Market Cap: $438.01M
• Dividend Yield: N/A
• Average Volume (3M): 164.41K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.48
• Revenue Growth: 54.77%
• EPS Growth: 37.35%
• Country: US
• Employees: 73
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.33
• Shares Outstanding: 15,560,009
• 10 Day Avg. Volume: 178,321
• 30 Day Avg. Volume: 164,409
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.15
• Enterprise Value/Revenue: 2.82
• Enterprise Value/Gross Profit: 2.82
• Enterprise Value/Ebitda: -1.53
• 1Y Price Target: $39.00
• Price Target Upside: 41.82% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 51 Neutral
• Price Target: $29.00 ▲(5.45% Upside)

The overall stock score is primarily impacted by significant financial challenges, including no revenue and persistent losses. While technical indicators show some positive momentum, the poor valuation due to negative earnings further weighs down the score.

Positive Factors

Innovative Product Pipeline

The positive interim data for ABI-5366 indicates strong potential for Assembly Biosciences' product pipeline, which could lead to successful commercialization and long-term revenue growth.

Strategic Partnerships

Strategic partnerships provide a steady revenue stream through milestone payments and royalties, enhancing financial stability and supporting R&D efforts.

Low Leverage

Low leverage indicates financial prudence, allowing the company to focus on R&D and strategic initiatives without the burden of high debt costs.

Negative Factors

Revenue Decline

The absence of revenue highlights operational challenges and raises concerns about the company's ability to generate income from its innovations.

Persistent Losses

Ongoing losses and negative cash flows indicate financial instability, which could hinder the company's ability to invest in future growth opportunities.

Declining Equity

The significant decline in equity reflects potential financial instability, limiting the company's capacity to absorb losses and invest in growth.

Assembly Biosciences Business Overview & Revenue Model

Company Description

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

How the Company Makes Money

Assembly Biosciences generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies that seek to leverage its innovative research and development capabilities. The company may receive milestone payments, licensing fees, and royalties from these partnerships as its products advance through clinical trials and achieve regulatory approvals. Additionally, Assembly Biosciences may also generate revenue from grants or funding aimed at supporting its research initiatives and clinical development programs. The success of its drug candidates in clinical trials and subsequent commercialization will be crucial in determining its long-term revenue potential.

Assembly Biosciences Financial Statement Overview

Summary

Assembly Biosciences exhibits financial distress with no revenue in recent years, persistent net losses, and negative cash flows. Despite low leverage, declining equity and assets indicate potential financial instability.

Income Statement

Assembly Biosciences has faced significant challenges with consistent revenue declines from $79.1M in 2020 to $0 in 2022 and 2024, indicating potential instability. The company has struggled with persistent net losses and negative profit margins, including a net profit margin of -100% in 2024. These factors highlight major profitability issues.

Balance Sheet

While the company maintains a reasonable equity ratio of 28% in 2024, indicative of some financial stability, the declining stockholders' equity from $240.6M in 2020 to $33.4M in 2024 raises concerns. A relatively low debt-to-equity ratio of 0.09 in 2024 suggests manageable leverage, but the shrinking equity indicates potential risk.

Cash Flow

Assembly Biosciences experiences significant volatility in free cash flow, with figures dropping sharply from $22.5M in 2023 to -$51.1M in 2024. The negative operating cash flow and free cash flow pose risks to future liquidity and financial health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	23.62M	28.52M	7.16M	0.00	6.25M	79.11M
Gross Profit	23.59M	28.39M	-41.74M	-498.00K	5.79M	79.00M
EBITDA	-43.42M	-45.42M	-64.20M	-92.59M	-91.93M	-64.78M
Net Income	-38.96M	-40.18M	-61.23M	-92.07M	-129.85M	-59.53M
Balance Sheet
Total Assets	80.78M	119.17M	136.82M	101.79M	191.06M	283.25M
Cash, Cash Equivalents and Short-Term Investments	74.98M	112.08M	130.25M	91.61M	146.63M	216.41M
Total Debt	2.88M	3.09M	2.34M	3.46M	6.48M	10.13M
Total Liabilities	62.68M	85.81M	95.73M	19.13M	22.13M	42.68M
Stockholders Equity	18.10M	33.36M	41.10M	82.66M	168.93M	240.58M
Cash Flow
Free Cash Flow	-55.85M	-51.15M	22.49M	-84.56M	-96.49M	-65.18M
Operating Cash Flow	-55.85M	-51.12M	22.74M	-84.46M	-93.40M	-62.96M
Investing Cash Flow	41.37M	40.17M	-69.14M	90.64M	26.52M	68.07M
Financing Cash Flow	19.27M	29.45M	13.82M	614.00K	53.06M	7.60M

Assembly Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 27.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ASMB, the sentiment is Positive. The current price of 27.5 is above the 20-day moving average (MA) of 26.58, above the 50-day MA of 25.21, and above the 200-day MA of 17.06, indicating a bullish trend. The MACD of 1.29 indicates Negative momentum. The RSI at 55.03 is Neutral, neither overbought nor oversold. The STOCH value of 46.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ASMB.

Assembly Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
QSI	55 Neutral	$445.49M	―	-46.87%	―	100.47%	-5.71%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ASMB	51 Neutral	$438.01M	-4.92	-147.64%	―	54.77%	37.35%
BNTC	47 Neutral	$415.54M	―	-42.31%	―	―	83.28%
LXEO	38 Underperform	$518.41M	―	-75.32%	―	―	-20.53%
ANNX	38 Underperform	$343.95M	―	-66.75%	―	―	-5.57%
VOR	33 Underperform	$189.98M	―	―	―	―	-686.12%

Assembly Biosciences Corporate Events

Assembly Biosciences Completes $175 Million Equity Financing

On August 8, 2025, Assembly Biosciences announced the pricing of a $175 million equity financing through an underwritten offering and a private placement. The offering, which closed on August 11, 2025, involved the sale of common stock and warrants, generating net proceeds of approximately $122 million. Additionally, Gilead Sciences participated in a private placement, contributing approximately $45 million. The funds raised will be used for general corporate purposes, potentially impacting Assembly Biosciences’ operations and market positioning by providing financial resources for ongoing and future projects.

The most recent analyst rating on (ASMB) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Assembly Biosciences stock, see the ASMB Stock Forecast page.

Assembly Biosciences Announces Positive Phase 1b Results

On August 8, 2025, Assembly Biosciences announced positive interim results from its Phase 1b clinical study of ABI-5366, a long-acting herpes simplex virus helicase-primase inhibitor candidate for recurrent genital herpes. The study showed a 94% reduction in HSV-2 shedding rate and genital lesion rate, and a 98% reduction in high viral load shedding rate compared to placebo, with the 350 mg weekly dose. The results exceeded the company’s targets and demonstrated a favorable safety profile, supporting the potential for once-weekly and once-monthly dosing regimens. These findings pave the way for Phase 2 clinical study preparations, with the company expecting to initiate these studies in mid-2026.

The most recent analyst rating on (ASMB) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Assembly Biosciences stock, see the ASMB Stock Forecast page.

Assembly Biosciences Reports Q2 2025 Progress and Financials

Assembly Biosciences is a biotechnology company focused on developing innovative therapeutics for serious viral diseases, including herpesvirus, hepatitis B virus (HBV), and hepatitis delta virus (HDV). In its second quarter 2025 financial report, Assembly Biosciences highlighted progress in its clinical trials, including positive topline data for its capsid assembly modulator candidate, ABI-4334, in chronic HBV patients, and interim data for ABI-6250 in HDV. The company is also on track to release proof-of-concept data for its herpes simplex virus candidates, ABI-5366 and ABI-1179, by fall 2025. Financially, Assembly Biosciences reported a net loss of $10.2 million for the quarter, with cash reserves projected to fund operations into mid-2026. Revenue from its collaboration with Gilead increased to $9.6 million, reflecting enhanced research and development activities. Looking ahead, Assembly Biosciences remains focused on advancing its clinical programs and achieving key milestones in the coming months.

Assembly Biosciences Reports Interim Results for ABI-6250

On August 6, 2025, Assembly Biosciences announced interim results from their Phase 1a clinical study of ABI-6250, a candidate for treating hepatitis delta virus (HDV). The company reported positive topline data from a Phase 1b study of ABI-4334 for chronic hepatitis B virus (HBV) and shared updates on their ongoing trials for herpes simplex virus (HSV) candidates ABI-5366 and ABI-1179. Financially, Assembly Biosciences reported a net loss of $10.2 million for the second quarter of 2025, with cash reserves projected to fund operations into mid-2026. The company continues to advance its clinical programs, aiming to deliver impactful datasets for its development candidates by the end of the year.

The most recent analyst rating on (ASMB) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Assembly Biosciences stock, see the ASMB Stock Forecast page.